Segmentation, Major Trends, and Competitive Analysis of the Cell Therapy Processing Market

The cell therapy processing market is gaining significant traction as advancements in gene and cell therapies continue to evolve. With increasing innovation and expanding manufacturing capabilities, this industry is set to experience remarkable growth over the coming years. Let's explore the market's expected size, key players, emerging trends, and detailed segment analysis.

Projected Size and Growth Path of the Cell Therapy Processing Market
The global cell therapy processing market is poised for rapid expansion, projected to reach $9.93 billion by 2030. This growth corresponds to a robust compound annual growth rate (CAGR) of 13.8%. Several factors underpin this expansion, including the growing commercialization of gene and cell therapies, amplified demand for contract manufacturing services, and the shift toward decentralized manufacturing approaches. Additionally, the increasing use of digital quality management systems and rising regulatory approvals for cell-based therapies are further propelling market growth. Key trends shaping the market include wider adoption of GMP-compliant processing platforms, scalable manufacturing solutions for cell therapies, integration of workflow automation software, expansion of contract processing services, and a heightened focus on sterility and quality assurance.

Download a free sample of the cell therapy processing market report:
https://www.thebusinessresearchcompany.com/report/cell-therapy-processing-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Companies Driving the Cell Therapy Processing Market
Several prominent companies are at the forefront of the cell therapy processing sector. These include Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Novartis AG, Gilead Sciences Inc., Danaher Corporation, Lonza Group AG, Anterogen Co. Ltd., Terumo Corporation, Sartorius AG, Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec GmbH, AGC Biologics S.p.A., MaxCyte Inc., Cellares Corporation, Cellectis S.A., JW Cayman Therapeutics Company Limited, Cell Therapies Pty Ltd., InGeneron Inc., WuXi Advanced Therapies, and Catalent Inc. A notable recent development includes AstraZeneca PLC's acquisition of ESO Biotech in May 2025 for $1 billion. This strategic move aims to bolster AstraZeneca's rare disease portfolio by integrating ESO Biotech's gene-editing innovations, enhancing their genomic medicine capabilities. ESO Biotech, based in Belgium, specializes in next-generation gene-editing therapies targeting rare diseases.

Emerging Trends Shaping the Cell Therapy Processing Industry
Innovation is a driving force in this market, with companies focusing on developing cutting-edge technologies. One such advancement is the adoption of wet-capable 5-axis computer numerical control (CNC) dental milling units, engineered for precise fabrication of dental restorations while maintaining material integrity through liquid coolant use. These systems offer high accuracy for complex geometries. For example, in March 2025, Roland DGA's DGSHAPE launched the DWX-43W Wet Milling Solution, a next-generation system designed for producing high-precision dental restorations. It features filter-free technology that eliminates the need for separate coolant filters, cutting operating costs by 20%. The system supports materials such as traditional ceramics, Chairside Zirconia, lithium disilicates, and titanium abutments. Bundled with DGSHAPE CAM software, it enables faster milling, streamlined workflows for up to six units simultaneously, and integrates with VPanel and DGSHAPE Cloud for real-time remote monitoring and enhanced workflow efficiency.

The cell therapy processing market is gaining significant traction as advancements in gene and cell therapies continue to evolve. With increasing innovation and expanding manufacturing capabilities, this industry is set to experience remarkable growth over the coming years. Let's explore the market's expected size, key players, emerging trends, and detailed segment analysis.

Projected Size and Growth Path of the Cell Therapy Processing Market
The global cell therapy processing market is poised for rapid expansion, projected to reach $9.93 billion by 2030. This growth corresponds to a robust compound annual growth rate (CAGR) of 13.8%. Several factors underpin this expansion, including the growing commercialization of gene and cell therapies, amplified demand for contract manufacturing services, and the shift toward decentralized manufacturing approaches. Additionally, the increasing use of digital quality management systems and rising regulatory approvals for cell-based therapies are further propelling market growth. Key trends shaping the market include wider adoption of GMP-compliant processing platforms, scalable manufacturing solutions for cell therapies, integration of workflow automation software, expansion of contract processing services, and a heightened focus on sterility and quality assurance.

Download a free sample of the cell therapy processing market report:
https://www.thebusinessresearchcompany.com/report/cell-therapy-processing-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Apr_PR
Leading Companies Driving the Cell Therapy Processing Market
Several prominent companies are at the forefront of the cell therapy processing sector. These include Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Novartis AG, Gilead Sciences Inc., Danaher Corporation, Lonza Group AG, Anterogen Co. Ltd., Terumo Corporation, Sartorius AG, Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec GmbH, AGC Biologics S.p.A., MaxCyte Inc., Cellares Corporation, Cellectis S.A., JW Cayman Therapeutics Company Limited, Cell Therapies Pty Ltd., InGeneron Inc., WuXi Advanced Therapies, and Catalent Inc. A notable recent development includes AstraZeneca PLC's acquisition of ESO Biotech in May 2025 for $1 billion. This strategic move aims to bolster AstraZeneca's rare disease portfolio by integrating ESO Biotech's gene-editing innovations, enhancing their genomic medicine capabilities. ESO Biotech, based in Belgium, specializes in next-generation gene-editing therapies targeting rare diseases.

Emerging Trends Shaping the Cell Therapy Processing Industry
Innovation is a driving force in this market, with companies focusing on developing cutting-edge technologies. One such advancement is the adoption of wet-capable 5-axis computer numerical control (CNC) dental milling units, engineered for precise fabrication of dental restorations while maintaining material integrity through liquid coolant use. These systems offer high accuracy for complex geometries. For example, in March 2025, Roland DGA's DGSHAPE launched the DWX-43W Wet Milling Solution, a next-generation system designed for producing high-precision dental restorations. It features filter-free technology that eliminates the need for separate coolant filters, cutting operating costs by 20%. The system supports materials such as traditional ceramics, Chairside Zirconia, lithium disilicates, and titanium abutments. Bundled with DGSHAPE CAM software, it enables faster milling, streamlined workflows for up to six units simultaneously, and integrates with VPanel and DGSHAPE Cloud for real-time remote monitoring and enhanced workflow efficiency.

Key Factors Driving Market Growth
The cell therapy processing market benefits greatly from increasing commercialization efforts in gene and cell therapies, which are becoming more accessible and widely adopted. This progress is complemented by a rising demand for contract manufacturing services, as many companies outsource production to specialized providers to ensure quality and scalability.

Expanding decentralized manufacturing and digital quality management systems are also significant contributors. Decentralized models allow production closer to the point of care, improving efficiency and reducing costs. Meanwhile, digital systems enhance oversight and compliance, ensuring high standards in processing.

Detailed Segment Breakdown of the Cell Therapy Processing Market
The market is categorized into several key segments:
1) Offering Type: Products, Services, and Software
2) Applications: Cardiovascular Diseases or Cardiac Regenerative Therapies, Bone Repair, Neurological Disorders, Skeletal Muscle Repair, Cancer, and Other Applications
3) End-Users: Research Institutes, Biopharmaceutical Companies, Contract Research Organizations, and Other End-Users

Further subcategories include:
- Products such as Cell Processing Systems, Cell Separation Devices, Cell Culture Equipment, Cell Preservation Systems, Consumables, and Reagents
- Services including Contract Manufacturing Services, Process Development Services, Quality Control and Testing Services, Logistics and Supply Chain Services, and Regulatory Compliance and Documentation Services
- Software offerings like Cell Processing Workflow Management Software, Data Analysis and Reporting Software, Quality Management Software, Laboratory Information Management Systems (LIMS), and Compliance and Audit Management Software

Geographic Insights and Market Outlook
While the report highlights a global view, specific regional trends and growth patterns underline the dynamic nature of the cell therapy processing market. North America remains a significant player, backed by strong R&D infrastructure and regulatory support. However, emerging markets are increasingly gaining momentum due to expanding healthcare infrastructure and growing biopharmaceutical activities. This broad geographic coverage provides a comprehensive understanding of where the industry is heading worldwide.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.